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TO THE EDITOR
Transglutaminases (TGs) are a family of
nine Ca2þ -dependent enzymes (types
1–7, band 4.2, factor XIII) that catalyze
cross-linking reaction resulting in the
formation of an Ne-(g-glutamyl lysine)
isopeptide bound between their sub-
strates (Griffin et al., 2002; Lorand and
Graham, 2003; Esposito and Caputo,
2005). TG-modified proteins are more
resistant to proteolytic degradation andAbbreviations: TG, Transglutaminase; hTG3, human TG3
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play a role in different biological
processes such as bone ossification
and cell–matrix interactions (TG2),
blood coagulation (factor XIII), semen
clotting (TG4), and epithelial differen-
tiation (TG1, TG3, and TG5) (Kim et al.,
1995b; Candi et al., 2002; Lorand and
Graham, 2003; Candi et al., 2005;
Eckert et al., 2005). Four members
(types 1–3, and 5) expressed in stratified
squamous epithelia such as the epider-
mis, and during the differentiation
process, are responsible for the forma-
tion of the cornified cell envelope
(Kalinin et al., 2002; Candi et al.,
2005). TG1 enzyme is expressed all
over the epidermis (from the lower to
the upper layers); the enzyme becomes
highly active on proteolitically proces-
sing, which occurs in the upper layers
of the epidermis. TG1 cross-links struc-
tural proteins, including involucrin,
loricrin, and small proline-rich proteins,
mutations abolishing its activity cause
lamellar ichthyosis (MIM 242300) in
human, whereas TG1 / mice die
soon after birth owing to incomplete
barrier function of the skin (Matsuki
et al., 1998; Kuramoto et al., 2002).
TG5 (Grenard et al., 2001) is expressed
in the upper layers of human epidermis
(Candi et al., 2002) and in human hair
follicle (Thibaut et al., 2005), mutations
abolishing its activity are associated to
acral peeling skin syndrome (MIM
609796) in human (Cassidy et al.,
2005). TG3 is expressed in the epider-
mis in the late differentiation stages
(Kim et al., 1995a; Lee et al., 1996) and
in the inner root sheath and in the
medullary layers of hair follicles, as
well as in the stomach, brain, and testis
(Hitomi et al., 2001). The native TG3
protein has a molecular mass of 77 kDa,
both in human and mice, it is proteo-
litically activated in a 47-kDa compo-
nent, containing the catalytic core and
a 30-kDa fragment (Ahvazi et al., 2003,
2004a). Recently, it has been shown
that, at least in vitro, cathepsin L is able
to cleave and activate TG3 (Cheng
et al., 2006). TG3, similar to TG1 and
TG5, crosslinks small proline-rich pro-
teins, loricrin, and involucrin during the
formation of the cell envelope. In vivo
and in vitro data show that these
enzymes (TG1, TG3, and TG5) use
different glutamine and lysine residues
(Hitomi et al., 2001) in the same protein
substrate, indicating that they act
synergistically to generate a functional
cell envelope. To date, no mutations or
disease are associated with TG3. Final-
ly, TG3 also seems involved in signal
transduction and, like two other TGs
(TG2 and TG5), is able to bind and
hydrolyze guanosine triphosphate (Liu
et al., 2002; Ahvazi et al., 2003; Ahvazi
et al., 2004a b; Candi et al. (2004)).
To study further the role of TG3 in
human and mouse skin (Institutional
approval of experiments and informed
consent of patients was obtained in
accordance with the Declaration of
Helsinki Principles), we detected the
presence of a new splicing variant
(Figure 1a), lacking exons 6 and 7
(D6,7) in mouse. The ablation of these
exons generates a new joining between
exons 5 and 8 with a shift in the original
reading frame, leading to the translation
of six new amino acids in exon 8
(Figure 1b), followed by a premature
stop codon. The new splicing variant
does not contain an important portion
of the catalytic site, as the catalytic
cysteine is located in exon 6. The
sequence analysis of flanking intron
sequence did not show any mutation
at the donor and the acceptor-splicing
site (data not shown). A specific PCR
analysis of other mouse strains demon-
strate the presence of the truncated
D6,7 isoform (data not shown). These
results demonstrated that the D6,7-
splicing variant originates during the
hnRNA processing and is not because
of a genomic mutation.
Furthermore, we also detected the
presence of a human TG3 (hTG3)
variant during the cloning of hTG3
cDNA. We observed the presence in
10% of the clones of a TG3 variant
lacking exons 9 and 10 (D9,10). The
ablation of these exons did not affect
the original reading frame (Figure 1d);
therefore, this new variant has the same
C-terminal end of the wild-type en-
zyme. The presence of the D9,10 hTG3
was confirmed by semi quantitative
PCR (Figure 1e), using cDNAs obtained
from differentiating normal human epi-
dermal keratinocytes and from skin
biopsies of normal individuals and
lamellar ichthyosis patients. As shown
in Figure 1e, we did not detect a
relevant difference of expression among
wild type and D9,10 TG3.
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Figure 1. Cloning and detection of mouse and hTG3-splicing variants. (a) EcoRI digestion of mouse TG3
(mTG3) in lanes 1, 3, and 4 .The D6,7 variant is represented by one band of 970 bp; in lane 2, two bands
of 920 bp, and 1,290 bp represents a wild-type (Wt) colony; the 3 kbp band is the empty vector
(amplification primers þACACCATCTCTGTCATTCCC, CTGGACAACATAGGCAACA). (b) Schematic
representation of mTG3-splicing variant. The gray box indicates the new six amino acids and the
premature stop codon. (c) EcoRI digestion of hTG, in lanes 3, 6, and 7; two bands of 840 and 1,270 bp
represents the Wt colonies, in lane 5 the band of 1,550 bp represents the D9,10 variant (amplification
primers þCTGAGAAGAGGCAGAGGAAGG, TCATTCGGCTACATCGATGGAC). (d) Schematic
representation of hTG3-splicing variant. (e) Semiquantitative reverse transcription–PCR on differentiated
normal human epidermal keratinocyte (0, 2, 4, 6, and 9 days with 1.2 mM Ca2þ ). The upper panel shows
the amplification of hTG3. The high-molecular-weight band is the Wt amplification (850 bp), whereas the
lower one is the spliced isoform (290 bp). The lower panel shows the housekeeping b-actin. (f)
Semiquantitative reverse transcription–PCR on RNA extracted from skin biopsies of normal (Wt) and
lamellar ichthyosis individuals (lanes 1, 2, 3, and 4). The upper band is the Wt band, the lower band
represents the spliced isoform, in the lower panel is shown the housekeeping (b-actin) (hTG3 primers:
þATGACACAGACCGAAATCT, ACTCATCTGGGACCTTGC).
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Guanosine triphosphatase activity is
lost both in mouse and human spliced
isoforms (D6,7; D9,10), because the
essential residues for such enzymatic
activity are located in the skipped
exons. However, the human D9,10-
splicing variant still retains the cross-
linking activity. In vitro measurement of
the crosslinking activity (Figure 2a, left
panel) demonstrated about four fold
reduction of activity in comparison
with wild-type enzyme. This is prob-
ably because of the lack of isoform of
the second Ca2þ -binding site in the
D9,10 , important for the activation of
the enzyme, as evaluated by the com-
puter modelling (Figure 2c–d).
Several studies reported that alterna-
tive splicing is a common phenomenon
in mammalian genomes, affecting be-
tween 35 and 59% of all human genes.
These mRNA variants could be consid-
ered ‘‘functional’’ when they are differ-
entially expressed and regulated in
support of specific functions of cellular
metabolism and ‘‘not functional’’ when
they are mostly produced from a partial
or inefficient processing of nuclear RNA
(hnRNA). In this paper, we describe the
isolation and characterization of two
novel TG3-splicing variants. The analysis
of in vitro differentiating keratinocytes,
skin biopsies from normal controls, and
from lamellar ichthyosis patients showed
that there is no significant difference in
the expression of the D9,10 hTG3
variant. In vitro Western blot experi-
ments revealed that the D9,10 protein
variant transfected in HEK293 cells is
expressed at lower level in comparison
with the wild-type protein (Figure 2b).
This is probably because of protein
instability of the D9,10 variant, as semi-
quantitative PCR analysis demonstrated
the same level of transcription (Figure 2a,
right panel).
In conclusion, we detected two
splicing variants for TG3, as the tran-
scription of these mRNAs appears to be
not regulated during differentiation and
in pathologies involving tranglutami-
nase activity (such us lamellar ichthyo-
sis), we believe that they do not have a
physiological role and it is possible to
speculate that they originate from an
error of the spliceosome complex.
Considering the low frequency of these
errors (Graveley, 2001), the existence
of TG1, TG2, and TG5 of splicing
variants in human (Aeschlimann et al.,
1998; Shevchenko et al., 2000; Candi
et al., 2001; Citron et al., 2001) is
probably because of a high degree of
sequence similarity and gene organiza-
tion (Grenard et al., 2001) within the
TG family. The identification and char-
acterization of these two splicing var-
iants for TG3 will contribute to
complete the knowledge in the field.
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Figure 2. Modelling and crosslinking activity of 9,10 hTG3 isoform. (a) Left panel: crosslinking activity
measurements of Wt and D9,10 hTG3 proteins; right panel: quantitative reverse transcription–PCR on
HEK-293-transfected cells (primers hTG3: þ TATCAGCATCTCCAGTCCTGCC,
GCCAATTCGGTTTGTGCTTCC; green fluorescent protein: þGCTGACCCTGAAGTTCATCTG,
TCTTGTAGTTGCCGTCGTCC on ABI 7500 þ SYBRII). (b) Western blot on transfected HEK-293 cells,
using anti-myc tag antibody, for TG3 Wt (80 kDa, lane 1) and D9,10 (55 kDa, lane 2) empty vector (lane
3). Housekeeping normalization, b-tubulin; transfection efficiency normalization, green fluorescent
protein. (c) Front and (d) back view of a model hTG3, the images are rotated 1801 with respect to each
other. The orange protein regions represent the portions missed by D9,10 alternative splicing. The yellow
circle (arrow) inside the orange region is the Ca2þ ion inside the Ca2þ second binding site.
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TO THE EDITOR
UVB irradiation of the skin induces a
complex cascade of acute inflamma-
tion, characterized by erythema, ede-
ma, and immunosuppression and is
according to chronic exposure subse-
quently linked to the initiation and
progression of skin cancer (Matsumura
and Ananthaswamy, 2004). The role of
inflammatory mediators in skin diseases
is of critical importance. This includesAbbreviations: F2-IsoPs, F2-isoprostanes; DCLF, diclofenac; COX, cyclo-oxygenase
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